 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
98 News |  |
| «12 |
- elezanumab (ABT-555) / AbbVie
Investigating the Safety and Efficacy of Elezanumab in Two Phase 2 Studies Enrolling Patients With Different Disease Courses of Multiple Sclerosis () - Jan 21, 2020 - Abstract #AAN2020AAN_3208;
P2
The RADIUS phase 2 studies are ongoing and designed to evaluate the safety and neurorestorative properties of elezanumab in patients with relapsing or progressive forms of MS.
- ||| elezanumab (ABT-555) / AbbVie
Enrollment closed, Enrollment change: RADIUS-P: A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis (clinicaltrials.gov) - Jan 21, 2020
P2, N=121, Active, not recruiting, Sponsor: AbbVie
The RADIUS phase 2 studies are ongoing and designed to evaluate the safety and neurorestorative properties of elezanumab in patients with relapsing or progressive forms of MS. Recruiting --> Active, not recruiting | N=90 --> 121
- ||| elezanumab (ABT-555) / AbbVie
Enrollment closed: RADIUS-R: A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Jan 21, 2020
P2, N=208, Active, not recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting | N=90 --> 121 Recruiting --> Active, not recruiting
- | elezanumab (ABT-555) / AbbVie
Trial completion date: RADIUS-P: A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis (clinicaltrials.gov) - Dec 5, 2019
P2, N=90, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Trial completion date: Jun 2021 --> Nov 2021
- | elezanumab (ABT-555) / AbbVie
Trial completion date: RADIUS-R: A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Feb 25, 2019
P2, N=165, Recruiting, Sponsor: AbbVie
Trial completion date: Jun 2021 --> Nov 2021 Trial completion date: May 2021 --> Aug 2021
- ||| elezanumab (ABT-555) / AbbVie
Enrollment open: RADIUS-P: A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis (clinicaltrials.gov) - Feb 8, 2019
P2, N=90, Recruiting, Sponsor: AbbVie
Trial completion date: May 2021 --> Aug 2021 Not yet recruiting --> Recruiting
- ||| elezanumab (ABT-555) / AbbVie
Enrollment open: RADIUS-R: A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Jan 14, 2019
P2, N=165, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | elezanumab (ABT-555) / AbbVie
New P2 trial: RADIUS-P: A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis (clinicaltrials.gov) - Nov 13, 2018
P2, N=90, Not yet recruiting, Sponsor: AbbVie
- | elezanumab (ABT-555) / AbbVie
New P2 trial: RADIUS-R: A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Nov 13, 2018
P2, N=165, Not yet recruiting, Sponsor: AbbVie
- elezanumab (ABT-555) / AbbVie
Trial completion date, Trial primary completion date: A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Mar 6, 2018
P1, N=20, Active, not recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Trial completion date: May 2019 --> Apr 2018 | Trial primary completion date: Jul 2018 --> Apr 2018
- elezanumab (ABT-555) / AbbVie
Enrollment closed, Enrollment change: A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Dec 5, 2017
P1, N=20, Active, not recruiting, Sponsor: AbbVie
Trial completion date: May 2019 --> Apr 2018 | Trial primary completion date: Jul 2018 --> Apr 2018 Recruiting --> Active, not recruiting | N=35 --> 20
- elezanumab (ABT-555) / AbbVie
Enrollment change, Trial termination, Trial primary completion date: [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Feb 8, 2017
P1, N=4, Terminated, Sponsor: AbbVie
Recruiting --> Active, not recruiting | N=35 --> 20 N=24 --> 4 | Suspended --> Terminated | Trial primary completion date: Aug 2017 --> Dec 2015; Company decision
- elezanumab (ABT-555) / AbbVie
Trial suspension, Trial primary completion date: [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Oct 19, 2016
P1, N=24, Suspended, Sponsor: AbbVie
N=24 --> 4 | Suspended --> Terminated | Trial primary completion date: Aug 2017 --> Dec 2015; Company decision Recruiting --> Suspended | Trial primary completion date: Sep 2016 --> Aug 2017
- elezanumab (ABT-555) / AbbVie
Enrollment open: A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Sep 12, 2016
P1, N=35, Recruiting, Sponsor: AbbVie
Recruiting --> Suspended | Trial primary completion date: Sep 2016 --> Aug 2017 Not yet recruiting --> Recruiting
- elezanumab (ABT-555) / AbbVie
Enrollment change, Trial primary completion date: A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Aug 9, 2016
P1, N=35, Not yet recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting N=60 --> 35 | Trial primary completion date: May 2017 --> Jul 2018
- elezanumab (ABT-555) / AbbVie
Enrollment open, Enrollment change: [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Apr 4, 2016
P1, N=24, Recruiting, Sponsor: AbbVie
N=60 --> 35 | Trial primary completion date: May 2017 --> Jul 2018 Suspended --> Recruiting | N=20 --> 24
- || elezanumab (ABT-555) / AbbVie
Trial initiation date: A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Jan 15, 2016
P1, N=60, Not yet recruiting, Sponsor: AbbVie
Suspended --> Recruiting | N=20 --> 24 Initiation date: Dec 2015 --> Jun 2016
- elezanumab (ABT-555) / AbbVie
Trial suspension: [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Dec 16, 2015
P1, N=20, Suspended, Sponsor: AbbVie
Initiation date: Dec 2015 --> Jun 2016 Recruiting --> Suspended
- | elezanumab (ABT-555) / AbbVie
New P1 trial: [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Nov 17, 2015
P1, N=20, Not yet recruiting, Sponsor: AbbVie
- ||| elezanumab (ABT-555) / AbbVie
New P1 trial: A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Nov 14, 2015
P1, N=60, Not yet recruiting, Sponsor: AbbVie